title: A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.
abstract: Chemotherapy and molecularly targeted approaches represent two very different modes of cancer treatment and each is associated with unique benefits and limitations. Both types of therapy share the overarching limitation of the emergence of drug resistance, which prevents these drugs from eliciting lasting clinical benefit. This review will provide an overview of the various mechanisms of resistance to each of these classes of drugs and examples of drug combinations that have been tested clinically. This analysis supports the contention that understanding modes of resistance to both chemotherapy and molecularly targeted therapies may be very useful in selecting those drugs of each class that will have complementing mechanisms of sensitivity and thereby represent reasonable combination therapies.
authors: Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA 92093-0660, USA.
authors: Kenta
authors: K
authors: Masui
authors: Beatrice
authors: B
authors: Gini
authors: Jill
authors: J
authors: Wykosky
authors: Ciro
authors: C
authors: Zanca
authors: Paul S
authors: PS
authors: Mischel
authors: Frank B
authors: FB
authors: Furnari
authors: Webster K
authors: WK
authors: Cavenee
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy*; D057285:Precision Medicine
chemical_list: D000970:Antineoplastic Agents